251.2

-0.83%↓

SAN

81.4

+0.28%↑

SHL.DE

45.79

-0.93%↓

ARGX

548.8

-1.72%↓

PHIA

23.14

+0.74%↑

251.2

-0.83%↓

SAN

81.4

+0.28%↑

SHL.DE

45.79

-0.93%↓

ARGX

548.8

-1.72%↓

PHIA

23.14

+0.74%↑

251.2

-0.83%↓

SAN

81.4

+0.28%↑

SHL.DE

45.79

-0.93%↓

ARGX

548.8

-1.72%↓

PHIA

23.14

+0.74%↑

251.2

-0.83%↓

SAN

81.4

+0.28%↑

SHL.DE

45.79

-0.93%↓

ARGX

548.8

-1.72%↓

PHIA

23.14

+0.74%↑

251.2

-0.83%↓

SAN

81.4

+0.28%↑

SHL.DE

45.79

-0.93%↓

ARGX

548.8

-1.72%↓

PHIA

23.14

+0.74%↑

Начало・Списък с акции・Galapagos NV

Galapagos NV

Отворен

СекторЗдравеопазване

26.9 -2.68

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

26.78

Максимум

27.68

Ключови измерители
By Trading Economics
Приходи	48M -106M
Продажби	-9.7M 65M
P/E Средно за сектора	53.92 34.393
EPS	-2.35
Марж на печалбата	-161.972
Служители	558
EBITDA	-48M

Препоръки
By TipRanks
Препоръки	Продай
12-месечна прогноза	-3.8% downside

Дивиденти
By Dow Jones
Следващи печалби	22.10.2025 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	55M 1.9B
Предишно отваряне	29.58
Предишно затваряне	26.9

Настроения в новините

By Acuity

50%

162 / 374 Класиране в Healthcare

Galapagos NV Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

11.08.2025 г., 17:49 ч. UTC

Значими двигатели на пазара

180 Life Sciences Stock Jumps on $156 Million Notes Sale

11.08.2025 г., 17:18 ч. UTC

Значими двигатели на пазара

Tiziana Life Sciences Rises After FDA Approves IND for Foralumab Trial

11.08.2025 г., 16:25 ч. UTC

Печалби

Correction to Constellation Software 2Q Revenue Rises, Profit Shrinks Article on Aug. 8

11.08.2025 г., 23:50 ч. UTC

Пазарно говорене

Nikkei May Rise as Yen Weakens -- Market Talk

11.08.2025 г., 23:42 ч. UTC

Пазарно говорене

Global Energy Roundup: Market Talk

11.08.2025 г., 23:42 ч. UTC

Пазарно говорене

Woodside's Share Price Implies Lofty Oil Price -- Market Talk

11.08.2025 г., 23:36 ч. UTC

Пазарно говорене

Gold Edges Higher on Likely Technical Recovery -- Market Talk

11.08.2025 г., 23:32 ч. UTC

Пазарно говорене

Argosy's New Bull Sees Sentiment Toward REITs Improving -- Market Talk

11.08.2025 г., 23:02 ч. UTC

Пазарно говорене

RBA Set to Lower OCR With New Forecasts in Focus -- Market Talk

11.08.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

11.08.2025 г., 20:37 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Bakkt Holdings: Andy Main Will Step Dn as Co-CEO and Director, Effective Aug 11, and Akshay Naheta Will Assume Role of CEO >BKKT

11.08.2025 г., 20:37 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Bakkt Holdings 2Q Rev $577.9M >BKKT

11.08.2025 г., 20:37 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Bakkt Holdings: In Upcoming Qtr, Will Conduct Comprehensive Review of Cost Structure to Ensure We Are Optimized, Driving Synergies Across Business, and Accelerating Path to Profitability >BKKT

11.08.2025 г., 20:22 ч. UTC

Печалби

Exodus Movement: Assets 2,058 Units of Bitcoin Valued at $220.5M, 2,729 Units of Ether Valued at $6.8M, $58.1M in Cash and Cash Equivalents, USD Coin, Treasury Bills as of June 30 >EXOD

11.08.2025 г., 20:22 ч. UTC

Печалби

Exodus Movement: Monthly Active Users 1.5M at End 2Q, Unchanged From 1.5M as of June 30, 2024 >EXOD

11.08.2025 г., 20:22 ч. UTC

Печалби

Exodus Movement: Processed Volume $1.38B in 2Q Dn 37% From 1Q, Bitcoin, Tether (TRX Network), Tether (ETH Network), USDC, SOL Top Assets Traded in 2Q >EXOD

11.08.2025 г., 20:22 ч. UTC

Печалби

Exodus Movement: Digital Assets and Liquid Assets $291.2M >EXOD

11.08.2025 г., 20:22 ч. UTC

Печалби

Exodus Movement 2Q Rev $25.8M >EXOD

11.08.2025 г., 20:14 ч. UTC

Пазарно говорене

Canada Dollar Faces Near-Term Weakness on Trade Row, September Rate-Cut Chatter -- Market Talk

11.08.2025 г., 19:12 ч. UTC

Пазарно говорене

Crude-Oil Futures Edge Up in Rangebound Trade -- Market Talk

11.08.2025 г., 18:56 ч. UTC

Пазарно говорене

U.S. Natural-Gas Futures Fall on Forecast Loss of Late August Heat -- Market Talk

11.08.2025 г., 18:31 ч. UTC

Пазарно говорене

Mining Halt Could Lift Lithium Prices in Near Term -- Market Talk

11.08.2025 г., 17:43 ч. UTC

Пазарно говорене

Freeport-McMoRan Can Push Up Prices, Profits With Copper Tariff Protection -- Market Talk

11.08.2025 г., 17:28 ч. UTC

Пазарно говорене

Crossborder Trade Tensions Accelerate Softness in Canada Rents -- Market Talk

11.08.2025 г., 17:16 ч. UTC

Пазарно говорене

Commodity Longs Fall to 11-Month Low -- Market Talk

11.08.2025 г., 16:42 ч. UTC

Придобивния, сливания и поглъщания

Adobe Stock Gets a Downgrade. 'AI Is Eating Software,' Analyst Says. -- Barrons.com

11.08.2025 г., 16:27 ч. UTC

Придобивния, сливания и поглъщания

BBVA Says Sabadell Offer Remains in Effect

11.08.2025 г., 16:26 ч. UTC

Придобивния, сливания и поглъщания

BBVA Previously Said It Won't Withdraw Offer to Buy Sabadell

11.08.2025 г., 16:25 ч. UTC

Придобивния, сливания и поглъщания

Banco de Sabadell Announced TSB Sale on July 1

11.08.2025 г., 16:25 ч. UTC

Придобивния, сливания и поглъщания

Banco de Sabadell Shareholders Approved TSB Unit Sale on Aug 6

Сравнение с други в отрасъла

Ценова промяна

Galapagos NV Прогноза

Ценова цел

By TipRanks

-3.8% надолу

12-месечна прогноза

Среден 26.3 EUR -3.8%

Висок 37 EUR

Нисък 19 EUR

Според 5 анализатори от Wall Street, предложили 12-месечна ценова цел за Galapagos NV през последните три месеца.

Консенсусна оценка

By TipRanks

Продай

5 ratings

Купи

Задържане

Продай

Според 5 анализатори, дали борсови рейтинги на Galapagos NV през последните 3 месеца.

Настроение

By Acuity

162 / 374 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Galapagos NV

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.